Home › NDC Lookup › RxCUI directory › RxCUI 307730

Acyclovir 40 MG/ML Oral Suspension — RxCUI 307730

RxNorm drug concept · Semantic clinical drug
RxCUI 307730 Semantic clinical drug · SCD ● Current RxNorm concept 10 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI307730
Official nameAcyclovir 40 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asacyclovir 200 MG per 5 ML Oral Suspension; acyclovir 200 MG in 5 mL Oral Suspension; acycycloguanosine 40 MG/ML Oral Suspension
FDA products mapped10
Package NDCs mapped14
Reported Medicaid activity (SDUD)59,478 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Acyclovir Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Acyclovir cream is used to treat cold sores — those small, painful blisters that appear on or around the lips, caused by the herpes simplex virus. It's approved for adults and teen...
  • What exactly is acyclovir cream used for?
  • The sooner the better — ideally at the very first tingle or sign of a cold sore coming on. For the ointment form, the standard schedule is every 3 hours, 6 times a day, for 7 days....
  • When should I start applying it, and how often?
📖 Read our full Acyclovir Topical guide →

🕸️ Concept Web — How Acyclovir 40 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Acyclovir 40 MG/ML Oral Suspension RxCUI 307730

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Acyclovir 281
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zovirax 152535
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Acyclovir Oral Suspension 370782
    • Acyclovir Oral Liquid Product 1153460
    • Acyclovir Oral Product 1153461
    • Acyclovir Oral Suspension [Zovirax] 366069
    • Zovirax Oral Liquid Product 1186463
    • Zovirax Oral Product 1186464
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Acyclovir 40 MG/ML 317612
    • Acyclovir 40 MG/ML Oral Suspension [Zovirax] 201903
    • Acyclovir 40 MG/ML [Zovirax] 566049

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Acyclovir 40 MG/ML SCDC · 317612
  • Acyclovir Oral Suspension SCDF · 370782
  • Acyclovir Oral Liquid Product SCDG · 1153460
  • Acyclovir Oral Product SCDG · 1153461

Brand-Name Concepts

  • Acyclovir 40 MG/ML Oral Suspension [Zovirax] SBD · 201903
  • Acyclovir 40 MG/ML [Zovirax] SBDC · 566049
  • Acyclovir Oral Suspension [Zovirax] SBDF · 366069
  • Zovirax Oral Liquid Product SBDG · 1186463
  • Zovirax Oral Product SBDG · 1186464
  • Zovirax BN · 152535

📦 FDA Products & Package NDCs

10 products · 14 package NDCs
14 package NDCs map to RxCUI 307730 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00472-0082-16 473 mL in 1 BOTTLE (0472-0082-16) Acyclovir Actavis Pharma, Inc. 2002-09-03
17856-2170-01 72 CUP, UNIT-DOSE in 1 CASE (17856-2170-1) / 5 mL in 1 CUP,... Acyclovir suspension Atlantic Biologicals Corp. 2026-05-04
17856-2170-02 72 CUP, UNIT-DOSE in 1 CASE (17856-2170-2) / 10 mL in 1 CUP... Acyclovir suspension Atlantic Biologicals Corp. 2026-05-04
17856-8083-01 50 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-8083-1) / 5 mL... Acyclovir ATLANTIC BIOLOGICALS CORP. 2025-10-01
31722-0681-47 473 mL in 1 BOTTLE (31722-681-47) Acyclovir Camber Pharmaceuticals, Inc. 2022-07-01
59651-0493-47 473 mL in 1 BOTTLE (59651-493-47) ACYCLOVIR Aurobindo Pharma Limited 2022-03-31
62135-0803-23 2 TRAY in 1 BOX (62135-803-23) / 10 CUP in 1 TRAY / 20 mL i... Acyclovir Chartwell RX, LLC 2025-03-20
62135-0803-24 2 TRAY in 1 BOX (62135-803-24) / 10 CUP in 1 TRAY / 5 mL in... Acyclovir Chartwell RX, LLC 2025-03-20
62135-0803-47 473 mL in 1 BOTTLE (62135-803-47) Acyclovir Chartwell RX, LLC 2023-11-30
68999-0803-23 2 TRAY in 1 BOX (68999-803-23) / 10 CUP in 1 TRAY / 20 mL i... Acyclovir Chartwell Governmental & Specialty RX, LLC. 2025-12-19
68999-0803-24 2 TRAY in 1 BOX (68999-803-24) / 10 CUP in 1 TRAY / 5 mL in... Acyclovir Chartwell Governmental & Specialty RX, LLC. 2025-12-19
70954-0188-10 473 mL in 1 BOTTLE (70954-188-10) acyclovir ANI Pharmaceuticals, Inc. 2020-07-13
72205-0170-72 473 mL in 1 BOTTLE (72205-170-72) Acyclovir suspension Novadoz Pharmaceuticals LLC 2023-10-23
72888-0079-17 473 mL in 1 BOTTLE (72888-079-17) Acyclovir Advagen Pharma Limited 2021-01-09
Observed labelers: Atlantic Biologicals Corp. (3) · Chartwell RX, LLC (3) · Chartwell Governmental & Specialty RX, LLC. (2) · Actavis Pharma, Inc. (1) · Advagen Pharma Limited (1) · ANI Pharmaceuticals, Inc. (1) · +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$0.0651
Range $0.0651–$0.0651 · middle 50% $0.0651–$0.0651 · 6 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.